image
Healthcare - Biotechnology - OTC - US
$ 0.0002
0.000003 %
$ 6.15 K
Market Cap
None
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CMRA stock under the worst case scenario is HIDDEN Compared to the current market price of 0.0002 USD, Comera Life Sciences Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CMRA stock under the base case scenario is HIDDEN Compared to the current market price of 0.0002 USD, Comera Life Sciences Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CMRA stock under the best case scenario is HIDDEN Compared to the current market price of 0.0002 USD, Comera Life Sciences Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CMRA

image
$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
633 K REVENUE
97.95%
-12 M OPERATING INCOME
-116.24%
-18 M NET INCOME
-230.24%
-9.77 M OPERATING CASH FLOW
-160.03%
-28.6 K INVESTING CASH FLOW
79.86%
5.24 M FINANCING CASH FLOW
-49.00%
136 K REVENUE
-56.73%
-2.16 M OPERATING INCOME
-45.73%
-2.15 M NET INCOME
-52.57%
-1.91 M OPERATING CASH FLOW
-92.65%
0 INVESTING CASH FLOW
100.00%
3.21 M FINANCING CASH FLOW
5172.31%
Balance Sheet Comera Life Sciences Holdings, Inc.
image
Current Assets 3.06 M
Cash & Short-Term Investments 447 K
Receivables 34.3 K
Other Current Assets 2.58 M
Non-Current Assets 664 K
Long-Term Investments 50 K
PP&E 571 K
Other Non-Current Assets 43.2 K
11.98 %69.28 %15.32 %Total Assets$3.7m
Current Liabilities 5.06 M
Accounts Payable 1.46 M
Short-Term Debt 655 K
Other Current Liabilities 2.95 M
Non-Current Liabilities 4.92 M
Long-Term Debt 120 K
Other Non-Current Liabilities 4.8 M
14.62 %6.56 %29.53 %48.08 %Total Liabilities$10.0m
EFFICIENCY
Earnings Waterfall Comera Life Sciences Holdings, Inc.
image
Revenue 633 K
Cost Of Revenue 210 K
Gross Profit 423 K
Operating Expenses 12.4 M
Operating Income -12 M
Other Expenses 6.03 M
Net Income -18 M
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)(20m)(20m)633k(210k)423k(12m)(12m)(6m)(18m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
66.77% GROSS MARGIN
66.77%
-1890.69% OPERATING MARGIN
-1890.69%
-2843.79% NET MARGIN
-2843.79%
288.20% ROE
288.20%
-483.06% ROA
-483.06%
1768.56% ROIC
1768.56%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Comera Life Sciences Holdings, Inc.
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)(10m)(10m)20212021Mar '21Mar '21Jun '21Jun '21Sep '21Sep '21Dec '21Dec '21Mar '22Mar '22Jun '22Jun '22Sep '22Sep '22Dec '22Dec '22
Net Income -18 M
Depreciation & Amortization 93.9 K
Capital Expenditures -28.6 K
Stock-Based Compensation 376 K
Change in Working Capital 2.55 M
Others 6.93 M
Free Cash Flow -9.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Comera Life Sciences Holdings, Inc.
image
CMRA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership Comera Life Sciences Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company's Board of Directors, to explore strategic alternatives to maximize shareholder value. globenewswire.com - 1 year ago
Comera Life Sciences Announces Process Exploring Strategic Alternatives WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. globenewswire.com - 1 year ago
Comera Life Sciences Appoints Dorothy Clarke to Board of Directors WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. globenewswire.com - 1 year ago
Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights – Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – globenewswire.com - 1 year ago
Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera's SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass. globenewswire.com - 1 year ago
These Are the ONLY 7 Penny Stocks to Consider in August 2023 Some of the most promising penny stocks can have multi-bagger potential over the long haul. After all, the combination of low prices, strong catalysts, and potentially high returns can be appealing. investorplace.com - 1 year ago
Comera Life Sciences Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies globenewswire.com - 1 year ago
Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights – Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – globenewswire.com - 1 year ago
Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ Platform WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a significant expansion of its SQore™ patent portfolio with the issuance of four new patents and two new notices of allowance. The six new patents, three issued in the United States and three covering Canada, Korea and India expand the number of proprietary viscosity reducing excipients in Comera's SQore platform and significantly broaden claims covered by previously issued patents. globenewswire.com - 1 year ago
Comera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients – Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to support product development needs – globenewswire.com - 1 year ago
Comera Life Sciences to Present at 22nd Annual PepTalk Conference WOBURN, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced it will present at the 22nd Annual PepTalk Conference, in San Diego on Wednesday, Jan. 18, 2023 at 5:15 p.m. PT. The conference will run from Monday, Jan. 16 through Friday, Jan. 20. globenewswire.com - 2 years ago
Comera Life Sciences to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it will be participating in the Benchmark Company's 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1, 2022 at the New York Athletic Club in New York. globenewswire.com - 2 years ago
8. Profile Summary

Comera Life Sciences Holdings, Inc. CMRA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 6.15 K
Dividend Yield 0.00%
Description Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Contact 12 Gill Street, Woburn, MA, 01801 https://comeralifesciences.com
IPO Date Dec. 21, 2020
Employees 12
Officers Mr. Michael G. Campbell CPA Chief Executive Officer, Chief Financial Officer & Principal Accounting Officer Dr. David Soane Ph.D. Co-Founder & Member of Scientific Advisory Board Ms. Janice Marie McCourt B.S., CLP, M.B.A., R.Ph. Chief Business Officer